Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cholesterol drug shows promise for seniors in 6-Month study

NCT ID NCT07489183

Disease control Sponsor: Dong Wha Pharmaceutical Co. Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the drug atostazet lowers cholesterol and affects blood sugar in people aged 65 and older with high cholesterol. Over 600 participants took the drug for 6 months, and researchers tracked side effects and changes in glucose metabolism. The goal was to confirm the drug's safety and effectiveness in this older population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atostazet
What this could lead to
If successful, this could confirm atostazet as a safe and effective option for lowering cholesterol in older adults.
What could go wrong
This is an observational study, not a randomized trial, so results may be less reliable. It only lasted 6 months, so long-term safety and benefits are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

641 people

The number who actually took part.

Started

Aug 2021

Finished

Sep 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with hypercholesterolemia at moderate risk or higher who are at least 65 years of age and confirmed for treatment

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males or females aged ≥ 65 years * Primary Hypercholesterolemia * moderate risk or higher patient based on Korean Guidelines for the Management of Dyslipidemia (the 4th edition) Exclusion Criteria: * Patients with a known hypersensitivity to any of the major or minor components of the study drug * Patients with active hepatic disease or unexplained persistently elevated serum aminotransferase levels * Patients with myopathies * Patients receiving glecaprevir and pibrentasvir

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypercholesterolemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hypercholesterolemia hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypercholesterolemia

Contacts and locations

Locations

  • Building 1897

    Seoul, 04516, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.